a Department of Medicine , Rochester Regional Health , Rochester , NY , USA.
b Department of Medicine , University of Rochester School of Medicine and Dentistry , Rochester , NY , USA.
Hum Vaccin Immunother. 2019;15(2):452-454. doi: 10.1080/21645515.2018.1534516. Epub 2018 Oct 23.
Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study. Streptococcal pneumonia serotype IgG titers were drawn at baseline, day 30, and day 180 after MM patients and controls received PCV13. Although vaccination with PCV13 produced a similar initial response in patients with multiple myeloma compared to control subjects, the duration of response may have waned in patients with multiple myeloma as compared to control subjects.
感染是多发性骨髓瘤（MM）患者发病率和死亡率的主要原因。这些患者表现出体液功能障碍，对肺炎球菌多糖疫苗（PPV23）的反应不佳。由于肺炎球菌结合疫苗（PCV13）可引起 T 细胞依赖性反应，因此建议多发性骨髓瘤患者使用。本研究比较了多发性骨髓瘤患者与正常对照者接种 PCV13 后的初始反应和 6 个月时的反应持久性。本研究纳入了 7 名多发性骨髓瘤患者和 18 名对照患者。在 MM 患者和对照组接受 PCV13 后，分别在基线、第 30 天和第 180 天抽取肺炎链球菌血清型 IgG 滴度。虽然与对照相比，PCV13 接种在多发性骨髓瘤患者中产生了类似的初始反应，但与对照相比，多发性骨髓瘤患者的反应持续时间可能已经减弱。
